Transaera, Inc. | $10,500,000 | (Nov 5, 2024)
Algebrik AI | $4,000,000 | (Nov 5, 2024)
Further | $4,100,000 | (Nov 5, 2024)
GLOX Therapeutics Ltd.
United Kingdom
- Glasgow
- 15/11/2023
- Unknown
- $5,362,000
Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
- Industry Biotechnology Research
- Website https://gloxtherapeutics.com/
- LinkedIn https://www.linkedin.com/company/glox-therapeutics-ltd/about/
Related People
James ClarkCo Founder
United Kingdom -
ND
Over the last twenty years Dr James Clark has held leadership positions within Precision Medicine companies including Response Genetics Inc., MDx Health, Enterome, Inivata, Enterobiotix Diadem, and Predictimmune. Most recently as CEO of Glox Therapeutics.
James has a proven track record in precision medicine, within medical device technology and product development in a number of diseases areas(oncology, microbiome, Inflammatory Bowel Disease and Alzheimer’s); as well as developing and implementing over ten successful commercial launches, with exceptional organisation/leadership skills and an extensive industry network.
James has developed over six laboratories in the US and Europe, holding Laboratory Director roles numerous times, and has led CLIA/CAP, ISO 15189 and ISO 13485 approvals
Since 2018 he has been part of the International Scientific Advisory Board for the ICCVs, focussing on the development of cancer vaccines.
Cintoo | $40,246,701 | (Nov 5, 2024)
Advex AI | $3,500,000 | (Nov 5, 2024)
Insider. | $500,000,000 | (Nov 5, 2024)
OpenOrigins | $4,500,000 | (Nov 1, 2024)
MealMe, Inc. | $8,000,000 | (Nov 1, 2024)
Persperity Health, Inc | $1,000,000 | (Nov 1, 2024)
Persana AI | $2,300,000 | (Nov 1, 2024)
Definition Health | $7,412,756 | (Nov 1, 2024)